扶正化瘀方对大鼠肝癌前病变细胞周期调控的影响  

The Effects of Fuzheng Huayu Decoction on the Cell Cycle Regulation in Hepatic Precancerosis Induced by DEN in Rats

作　　者：任公平[1] 张忠敏[1] 孙琳林[1] 那辉[1] 

机构地区：[1]牡丹江医学院红旗医院中西医结合科,黑龙江牡丹江157011

出　　处：《临床医学工程》2011年第11期1699-1700,共2页Clinical Medicine & Engineering

基　　金：黑龙江省中医药科研项目(ZHY10-Z108)

摘　　要：目的探讨扶正化瘀方对大鼠肝癌前病变细胞周期调控因子CyclinD1、CDK4蛋白表达的影响,揭示扶正化瘀方治疗肝癌前病变的机制及其效果。方法将80只清洁级SD雄性大鼠随机分为空白组、单纯致癌组、扶正化瘀方组、苦参素组,每组20只。除空白组外,其他组以二乙基亚硝胺(DEN)诱导大鼠肝癌前病变模型,应用扶正化瘀方、苦参素对其诱癌过程实施全程干预,共17周。各组大鼠在饲养l8周后取材,利用免疫组化对CyclinD1、CDK4蛋白表达及肝组织病理形态学进行观察。结果扶正化瘀方组、苦参素组大鼠肝脏病变均明显轻于单纯致癌组,与空白组相比,单纯致癌组大鼠肝组织CyclinD1、CDK4蛋白表达明显增高(P<0.05)。扶正化瘀方组、苦参素组CyclinD1、CDK4蛋白表达较单纯致癌组均明显减少(P<0.05);扶正化瘀方组与苦参素组比较有显著差异(P<0.05)。结论扶正化瘀方可有效阻断大鼠肝癌前病变,其作用机制可能与下调细胞周期调控因子CyclinD1、CDK4蛋白表达有关。Objective To investigate the effects of Fuzheng Huayu decoction on the expression of CyclinD1 and CDK4 protein in precancerous lesions of liver cancer induced with DEN in rats, and reveal the treatment mechanism. Methods Eighty SD rats were randomly divided into four groups： blank group, model group, Fuzheng Huayu decoction group and Oxymatrine group. During the experiment, Fuzheng Huayu decoction and Oxymatrine injection were used to interfere the hepatocarcinogenesis induced by DEN in rats. After 18 wk, the expression of CyclinD1 and CDK4 protein of hepatocyte was detected with immunohistochemistry technology. Results Compared with that in the model group, pathological changes in liver tissue of Fuzheng Huayu decoction group and Oxymatrine group had obviously improved; The expression of CyclinD1 and CDK4 protein of the two treatment groups was significantly different from that in the model group （P 0.05）. Between the Oxymatrine group and Fuzheng Huayu decoction group, the expression of CyclinD1 and CDK4 protein had distinctly statistical difference （P 0.05）. Conclusion Fuzheng Huayu decoction can effectively prevent the precancerous lesions of liver cancer in rats, which is related to regulate expression of Cyclin D1, CDK4.

关 键 词：肝癌前病变 扶正化瘀方 CYCLIND1 CDK4 

分 类 号：R735.7[医药卫生—肿瘤] R256.4[医药卫生—临床医学]